http://www.americanbankingnews.com/getthestreet reaffirmed their buy rating on shares of Monsanto (NYSE: MON) in a research note released on Wednesday morning.

“Monsanto Company (MON) has been reiterated by TheStreet Ratings as a buy with a ratings score of A . The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”

,” TheStreet’s analyst commented.

Monsanto traded up 0.71% on Wednesday, hitting $101.75. Monsanto has a 52-week low of $69.70 and a 52-week high of $104.19. The stock’s 50-day moving average is currently $101.4. The company has a market cap of $54.519 billion and a price-to-earnings ratio of 24.08.

The company also recently declared a quarterly dividend, which is scheduled for Friday, April 26th. Shareholders of record on Friday, April 5th will be given a dividend of $0.38 per share. This represents a $1.50 dividend on an annualized basis and a yield of 1.48%. The ex-dividend date of this dividend is Wednesday, April 3rd.

A number of other analysts have also recently weighed in on MON. Analysts at Atlantic Securities downgraded shares of Monsanto from a neutral rating to an underweight rating in a research note to investors on Tuesday, February 19th. Separately, analysts at Piper Jaffray raised their price target on shares of Monsanto from $120.00 to $130.00 in a research note to investors on Monday, February 11th. They now have an overweight rating on the stock. Finally, analysts at Susquehanna set a $125.00 price target on shares of Monsanto in a research note to investors on Friday, January 18th.

Fifteen analysts have rated the stock with a buy rating, six have assigned a hold rating, and one has given an underweight rating to the stock. The company currently has an average rating of overweight and an average target price of $111.62.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.